Storia in 3 fonti

Glenmark gets US approval for expanded paediatric use of SAR drug

Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older

Raccontata da

healio.com

thehindubusinessline.com

economictimes.indiatimes.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo1 mese fa

Glenmark gets US approval for expanded paediatric use of SAR drug

Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older

originale

economictimes.indiatimes.com1 mese fa

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms of seasonal allergic rhinitis…

Leggi questa versione → originale

Timeline cronologica

martedì 21 luglio 2026·healio.com
FDA expands Ryaltris approval to include children aged 6 to 11 years
The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged…
martedì 21 luglio 2026·thehindubusinessline.com
Glenmark gets US approval for expanded paediatric use of SAR drug
Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older

Glenmark gets US approval for expanded paediatric use of SAR drug

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

Timeline cronologica

FDA expands Ryaltris approval to include children aged 6 to 11 years

Glenmark gets US approval for expanded paediatric use of SAR drug

FDA expands Ryaltris approval to include children aged 6 to 11 years

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray